Results by group676

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 676

Outcome	Group	Category	Value	Spread	Units
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the Overall Population	GSK1572932 Group		0.17		events/person-years
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the Overall Population	Placebo Group		0.168		events/person-years
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the No-CT Population	GSK1572932 No-CT Group		0.169		events/person-years
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the No-CT Population	Placebo No-CT Group		0.178		events/person-years
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the CT Population	GSK1572932 CT Group		0.172		events/person-years
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the CT Population	Placebo CT Group		0.158		events/person-years
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the Overall Population	GSK1572932 Group		0.082		events/person-years
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the Overall Population	Placebo Group		0.081		events/person-years
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the No-CT Population	GSK1572932 No-CT Group		0.084		events/person-years
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the No-CT Population	Placebo No-CT Group		0.086		events/person-years
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the CT Population	GSK1572932 CT Group		0.08		events/person-years
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the CT Population	Placebo CT Group		0.076		events/person-years
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the Overall Population	GSK1572932 Group		0.064		events/person-years
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the Overall Population	Placebo Group		0.061		events/person-years
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the No-CT Population	GSK1572932 No-CT Group		0.064		events/person-years
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the No-CT Population	Placebo No-CT Group		0.06		events/person-years
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the CT Population	GSK1572932 CT Group		0.063		events/person-years
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the CT Population	Placebo CT Group		0.063		events/person-years
Kaplan-Meier Estimate (KME) of 2, 3, 4 and 5-year as Regards Disease-free Survival (DFS) in the Overall Population	GSK1572932 Group	DFS KME at 2Y - Overall Population	65.57	95% Confidence Interval 63.08 to 67.95	percent probability
Kaplan-Meier Estimate (KME) of 2, 3, 4 and 5-year as Regards Disease-free Survival (DFS) in the Overall Population	Placebo Group	DFS KME at 2Y - Overall Population	65.5	95% Confidence Interval 61.94 to 68.81	percent probability

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00480025/results

API reference For AI assistants

Results by group676

Sources 3

Read this list from software.